Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry.
|Title||Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Dzimianski, John V., Lorig-Roach Nicholas, O'Rourke Sara M., Alexander David L., Kimmey Jacqueline M., and DuBois Rebecca M.|
|Date Published||2020 Jul 19|
Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated "dip-and-read" format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete quantitative results are obtained in less than 20 minutes. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens.
|PubMed Central ID||PMC7388487|
|Grant List||HHSN272201400008C / AI / NIAID NIH HHS / United States |
S10 OD027012 / OD / NIH HHS / United States